A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients

Inclusion Criteria: * Patient must be age ≥ 18 years. * Patient must have a confirmed cancer diagnosis for which VEGFRi treatment is indicated, and must be currently under VEGFRi-based anti-cancer therapy with stable dosage for ≥ 1 week. This treatment may be VEGFRi monotherapy or VEGFRi-based combination therapy, so long as it does not include prohibited therapies. * Patient must have shown signs of HFSR that meet (for Part 1) the NCI CTCAE v5.0 - PPE grade 2 or higher OR (for Part 2) IGA-HFSR criteria of grade 3 or higher. * Patient on pain medications is allowed provided they have been on stable dosage in the past 1 week and is going to continue at the same dosage. * Patient is able to use topical medications and complete questionnaires reliably. * Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2. * Patient must have the ability to understand and the willingness to sign a written informed consent prior to study entry. Exclusion Criteria: * Patient with unresolved hand or foot skin disorders (NCI CTCAE v5.0 grade 2 or higher) due to other medications within 4 weeks prior to study entry. * Patient who is using other topical medications in the hands or feet area and cannot stop such usage \>7 days ahead of randomization. * Patient who is using other concurrent cancer medications, such as capecitabine, pegylated liposomal doxorubicin, 5-fluorouracil, dabrafenib, vemurafenib, doxorubicin, docetaxel, cytarabine, ramucirumab and bevacizumab, which may result in …